Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. ATRIPLA (efavirenz/ emtricitabine/ fumarate de ténofovir disoproxil)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

ATRIPLA (efavirenz/ emtricitabine/ fumarate de ténofovir disoproxil)

Medicine - Posted on Sep 06 2019
Active substance (DCI)
  • efavirenz
  • emtricitabine
  • fumarate de ténofovir disoproxil
history (3)
  • 7/10/19

    ATRIPLA (efavirenz/ emtricitabine/ fumarate de ténofovir disoproxil)

    Maintien du remboursement dans les mêmes conditions
    icône flèche
  • 6/17/15

    ATRIPLA (efavirenz+emtricitabine+tenofovir disoproxil fumarate), antiviral combination

    Second-line treatment in the management of HIV ATRIPLA has Marketing Authorisation in the treatment of HIV-1 infection in ad...
    icône flèche
  • 1/21/09

    ATRIPLA

    INFECTIOLOGIE – NOUVELLE ASSOCIATION ATRIPLA, efavirenz / emtricitabine / ténofovir disoproxil, association d’antirétrovirau...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • J05AR06
Manufacturer
GILEAD SCIENCES
Presentation

ATRIPLA 600 mg/200 mg/245 mg, comprimé pelliculé (code CIS : 64005832)
flacon(s) polyéthylène haute densité (PEHD) de 30 comprimé(s) avec fermeture de sécurité enfant - Code CIP : 34009 383 069 9 6

All our publications
    Drug therapy Immunologic deficiency syndromes Sexually transmitted diseases Virus diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
UbF6uX81nt8VCvZn